Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE): Quality and safety in the implementation of medicinal cannabis use in the community

澳大利亚大麻素临床和研究卓越中心 (ACRE)：社区药用大麻使用的质量和安全性

• 批准号: nhmrc : GNT1135054
• 负责人: Dr Amirali Popat
• 金额: $ 249.85万
• 依托单位国家: 澳大利亚
• 项目类别: Centres of Research Excellence
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/australian-centre-cannabinoid-use-community/1347973
• 关键词: Australian; Centre; Cannabinoid; Clinical; Research

Australia has a world-first opportunity to develop rigorous medical cannabis research based on quality clinical and environmental science that tests and selects cannabis constituents affecting health and sickness. It will be able to design and coordinate dose and formulation-finding studies to assess safety and efficacy of different cannabinoids. This information will enable registration of products for health that have been thoroughly researched and tested to levels acceptable for public use.

澳大利亚拥有世界上第一个在高质量临床和环境科学的基础上开发严格的医用大麻研究的机会，该科学测试和选择影响健康和疾病的大麻成分。它将能够设计和协调剂量和配方寻找研究，以评估不同大麻类药物的安全性和有效性。这些信息将使那些经过彻底研究和测试达到公众可接受使用水平的健康产品得以注册。